Lates News

Every Economist AI newsletter, Donghai Securities published a research report on March 27 giving Boya Bio (300294.SZ) a "buy" rating. The reasons for the rating mainly include: 1) The decline in profit margins is significant due to the impact of large provision; 2) The revenue growth of the blood products business is increasing, but the gross profit margin is under short-term pressure; 3) Plasma collection volume is steadily increasing, and product pipeline is continuously expanding. (Daily Economic News)